Luye Pharma Group (HK:2186) has released an update.
Luye Pharma Group Ltd. has announced that their long-acting injectable antipsychotic, Meibirui, received marketing approval in China for the treatment of schizophrenia, a condition affecting approximately 8 million people in the country. Meibirui offers a monthly dose, which can improve patient compliance and prevent relapse. The company, known for its diversified Central Nervous System product portfolio, remains a strong player in the global market for LAI antipsychotics, which saw worldwide sales reach US$5 billion in 2023.
For further insights into HK:2186 stock, check out TipRanks’ Stock Analysis page.
